Papillary Renal Cell Carcinoma

This multi-omics bioinformatics study investigated the significance of TOP2A in renal cell carcinoma subtypes KIRC, KIRP, and KICH. Analyses revealed significant TOP2A overexpression associated with advanced pathological stages, high tumor grades, and poor patient outcomes. Genomic alterations, primarily amplifications and mutations, were identified at the TOP2A locus. The study suggests that TOP2A regulates the cell cycle, influences the immune microenvironment, and modulates key signaling pathways, positioning it as a prognostic biomarker and a potential therapeutic target.

The phase III COSMIC-313 study investigated the addition of cabozantinib to nivolumab and ipilimumab in previously untreated patients with advanced renal cell carcinoma. Final results confirmed a significant progression-free survival (PFS) benefit for the triplet regimen (16.6 months vs 11.2 months for the doublet). However, no significant improvement in overall survival (OS) was observed. Exploratory biomarker analyses suggest that patients with higher levels of M2-like macrophages might experience improved PFS and OS with the triplet therapy.